-
2023-504863-17-00
5
2024-02-21
1. Lupus Erythematosus, Cutaneous, Subacute
2. Chronic Cutaneous Lupus
-
2023-503327-26-00
5
2024-01-31
Sjogren's syndrome
-
2022-502980-39-00
5
2024-01-25
Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
-
2022-503092-28-00
5
2024-01-08
Relapsed/Refractory Follicular Lymphoma
-
2023-505911-19-00
4
2024-01-05
Acute Myeloid Leukemia
-
2023-504807-94-00
7
2023-12-26
Breast Cancer; Advanced solid tumors including but not limited to gyne
-
2022-503114-23-00
3
2023-12-19
Breast Cancer
-
2022-502775-29-01
5
2023-12-14
Early stage Follicular Lymphoma
-
2023-509793-38-00
4
2023-11-24
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or CLL-like mo
-
2023-503224-66-00
5
2023-10-31
Atrial Fibrillation
-
2023-503295-25-00
10
2023-10-31
Resectable biliary tract cancers
-
2022-502597-16-00
9
2023-10-27
Intermediate or High-risk Primary or Secondary
Myelofibrosis
-
2023-503661-28-00
5
2023-10-26
Hidradenitis Suppurativa
-
2023-504602-11-00
5
2023-10-25
Mild to moderate Alzheimer's disease
-
2024-511961-12-00
10
2023-10-12
Knee osteoarthritis
-
2023-510541-25-00
1
2023-10-09
Relapsed/Refractory B-cell Malignancies
-
2022-502160-20-00
5
2023-10-02
Idiopathic Immune Complex Mediated Membranoproliferative Glomeruloneph
-
2024-513562-19-00
5
2023-08-30
End-Stage Kidney Disease
-
2022-501308-90-00
4
2023-05-24
Molecularly selected and resectable primary colorectal cancer
-
2022-501808-96-00
4
2023-05-15
Mantle Cell Lymphoma
-
2024-511631-10-00
9
2023-02-27
Hodgkin’s lymphoma
-
2023-505634-94-00
10
2023-02-02
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythe
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer